摘要
目的探讨诺欣妥(沙库巴曲缬沙坦钠片)联合恩格列净对射血分数降低心力衰竭(HFrEF)患者心血管的保护作用。方法前瞻性抽取2019年1月至2022年12月安阳市第三人民医院收治的104例HFrEF患者,按照随机数字表法分为观察组与对照组,每组52例。对照组给予诺欣妥治疗,观察组在对照组基础上增加恩格列净治疗。比较两组治疗前后超声心功能指标[左室短轴缩短率(FS)、左心室射血分数(LVEF)、左心室舒张末期容积(LVEDV)]水平、心率(HR)、血清N末端脑钠肽前体(NT-proBNP)水平、6 min步行试验(6MWT)结果,比较两组不良结局及不良反应发生情况。结果治疗后,观察组FS、LVEF水平均高于对照组,LVEDV水平低于对照组(P<0.05)。治疗后,观察组6MWT水平高于对照组,HR、NT-proBNP水平均低于对照组(P均<0.05)。随访6个月,两组主要心血管不良事件发生率、全因死亡率比较差异均未见统计学意义(P均>0.05),观察组再住院率低于对照组(P<0.05)。治疗期间,观察组不良反应总发生率(13.46%,7/52)与对照组(11.54%,6/52)比较差异未见统计学意义(P>0.05)。结论恩格列净联合诺欣妥治疗HFrEF患者,可改善患者的心功能,延缓心室重构,降低心力衰竭再住院率,且安全性较高。
Objective To investigate the cardioprotective effect of entresto(eacubitril/valsartan)in combination with empagliflozin in patients with heart failure with reduced ejection fraction(HFrEF).Methods A prospective analysis was conducted on 104 HFrEF patients admitted to Anyang Third People’s Hospital from January 2019 to December 2022.And the selected patients were assigned into the observation group and the control group by random number table method,with 52 cases in each group.The control group was treated with entresto,and the observation group was treated with empagliflozin based on the treatment of the control group.Then the echocardiographic indices of cardiac function,including fraction shorting(FS),left ventricular ejection fraction(LVEF)and left ventricular end-diastolic volume(LVEDV),heart rate(HR),N-terminal pro-brain natriuretic peptide(NT-proBNP),six-minute walking test(6MWT)result of the two groups were compared before and after treatment.The incidence of adverse outcomes and adverse reactions were compared between the two groups.Results After treatment,the observation group had larger FS,higher LVEF,and smaller LVEDV compared with the control group(P<0.05).After treatment,the observation group showed a considerably longer distance in 6MWT,and had lower levels of HR and NT-proBNP compared with the control group(all P<0.05).There was no significant difference in the incidence of major adverse cardiac events and all-cause mortality between the two groups during the 6-month follow-up(all P>0.05).The re-hospitalization rate of the observation group was lower than that of the control group,and the difference was statistically significant(P<0.05).During the treatment period,there was no significant difference in the total incidence of adverse reactions between the observation group(13.46%,7/52)and the control group(11.54%,6/52),P>0.05.Conclusions In HFrEF patients,empagliflozin combined with entresto has significant effects on improving cardiac function,delaying ventricular remodeling,and reducing the rate
作者
杨登云
李志飞
Yang Dengyun;Li Zhifei(Department of Cardiology I,Anyang Third People’s Hospital,Anyang 455000,China)
出处
《中国实用医刊》
2024年第10期97-100,共4页
Chinese Journal of Practical Medicine
关键词
诺欣妥
恩格列净
射血分数降低心力衰竭
心血管保护作用
心功能
不良结局
Sacubitril and valsartan sodium hydrate drug combination
Empagliflozin
Heart failure with reduced ejection fraction
Cardiovascular protection
Cardiac function
Adverse outcomes
